AGTR1 and kidney transplant: The serum antibodies that target the AT1 receptor have been shown to contribute to vascular allograft rejection in kidney transplant patients; however, treatment with losartan, an AT1 receptor antagonist, blocked the agonistic AT1 receptor response to the antibodies [79].